Vivos Therapeutics, Inc. has announced that its VidaSleep™ oral appliance, equipped with FDA-cleared Unilateral Bite Block technology, has received approval from the Centers for Medicare & Medicaid ...

LITTLETON, Colo., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for ...

(“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health ...

On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and ...

LITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive ...

LITTLETON, Colo., May 01, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods ...

In much the same way that they’re designed to expand wearers’ upper airways, Vivos Therapeutics’ slate of oral appliances have now expanded their FDA indications, too. Collectively known as the ...

Credit: Vivos Therapeutics. The FDA clearance was based on data from 73 patients with severe OSA. The Food and Drug Administration (FDA) has cleared the Vivos CARE (complete airway repositioning ...

CEO Kirk Huntsman highlighted significant progress in 2024, including a 26% growth in product revenue and a 21% reduction in operating expenses. This resulted in a 35% reduction in operating loss for ...

LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea ...